SCHEMBL6851071

SCHEMBL6851071

O=C(CCCc1ccc(Cl)cc1)NCC1CCc2ncn(C(c3ccccc3)(c3ccccc3)c3ccccc3)c2C1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCR2 P41597 5/20 0.43
LMNA P02545 1/20 0.38
LTA4H P09960 2/20 0.38
FAAH O00519 1/20 0.37
BCHE P06276 1/20 0.37
ACHE P22303 1/20 0.37
HDAC3 O15379 2/20 0.36
HDAC4 P56524 2/20 0.36
HDAC1 Q13547 2/20 0.36
HDAC7 Q8WUI4 2/20 0.36
HDAC2 Q92769 2/20 0.36
HDAC10 Q969S8 2/20 0.36
HDAC11 Q96DB2 2/20 0.36
HDAC8 Q9BY41 2/20 0.36
HDAC6 Q9UBN7 2/20 0.36
HDAC9 Q9UKV0 2/20 0.36
HDAC5 Q9UQL6 2/20 0.36
HRH3 Q9Y5N1 2/20 0.36
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6849628 0.95 CCR2 (0.41) CCR2LTA4HFAAHBCHEACHE
SCHEMBL6849769 0.93 CCR2 (0.43) CCR2LMNALTA4HFAAHBCHE
SCHEMBL6851333 0.90 CCR2 (0.41) CCR2LMNAFAAHBCHEACHE
SCHEMBL6849558 0.88 CCR2 (0.41) CCR2LTA4HFAAHBCHEACHE
SCHEMBL6846987 0.82 CCR2 (0.41) CCR2LMNAFAAHBCHEACHE
SCHEMBL6850900 0.73 CHRM3 (0.31)
SCHEMBL6967614 0.72 SIGMAR1 (0.41) HRH3MEN1KMT2A
SCHEMBL6846803 0.72 CCR2 (0.41) CCR2LMNALTA4HBCHEACHE
SCHEMBL6851108 0.71 LMNA (0.41) LMNAMEN1KMT2ARAB9A
SCHEMBL1417680 0.69 PDK1 (0.34)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6756384-B2 TREATMENT OF DISEASES AND DISORDERS RELATED TO THE HISTAMINE H3 RECEPTOR. NOVO NORDISK A/S (DK) 2004-06-29 US disclosed
US-20030135056-A1 Imidazole compounds HIGH POINT PHARMACEUTICALS, LLC 2003-07-17 US disclosed
US-6437147-B1 FOR THERAPY OF DISEASES OF CENTRAL NERVOUS SYSTEM, PERIPHERAL NERVOUS SYSTEM, CARDIOVASCULAR SYSTEM, PULMONARY SYSTEM, GASTROINTESTINAL SYSTEM AND ENDOCRINOLOGICAL SYSTEM NOVO NORDISK (DK) 2002-08-20 US disclosed
US-20020058659-A1 Imidazole compounds HIGH POINT PHARMACEUTICALS, LLC 2002-05-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030135056-A1 Imidazole compounds HRH3, HRH4, HRH2 CCR2 707/4885LMNA 4098/4885LTA4H 415/4885
US-20020058659-A1 Imidazole compounds HRH3, HRH4, HRH2 CCR2 707/4885LMNA 4098/4885LTA4H 415/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.